Preferred Label : Fluorine F 18 PSMA-1007;
NCIt synonyms : Fluorine-18 PSMA-1007; 18F-PSMA-1007; [18F]-PSMA-1007; PSMA-1007 F-18; 18FPSMA-1007; F-18-PSMA-1007;
NCIt definition : A radioconjugate containing the human prostate-specific membrane antigen (PSMA)-targeting
ligand, PSMA-1007, labeled with the radioisotope fluorine F 18, with potential imaging
activity using positron emission tomography/computed tomography (PET/CT). Upon administration
of fluorine F 18 PSMA-1007, the PSMA-1007 moiety targets and binds to PSMA-expressing
tumor cells. This allows for visualization of PSMA-expressing cells upon imaging.
PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed
on the membrane of prostatic epithelial cells and strongly overexpressed in prostate
cancer (PCa) cells, with its level rising with increasing tumor differentiation and
in hormone-refractory cancers.;
UNII : F1CB00L2RH;
CAS number : 2093321-19-6;
NCI Metathesaurus CUI : CL972323;
Origin ID : C167348;
UMLS CUI : C5238480;
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
concept_is_in_subset
has_target
https://www.has-sante.fr/jcms/p_3368278/fr/radelumin-18f-psma-1007
2022
false
false
false
France
Fluorine F 18 PSMA-1007
insurance, health, reimbursement
prostatic neoplasms
neoplasm recurrence, local
PSMA-1007
Positron-Emission tomography
radiopharmaceuticals
fluorine radioisotopes
injections, intravenous
Biochemically Recurrent Prostate Carcinoma
PSMA-1007 (18F)
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3337433/fr/radelumin-18f-psma-1007-cancer-de-la-prostate
https://www.has-sante.fr/jcms/p_3337451/fr/decision-n-2022-0144/dc/sem-du-28-avril-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-radelumin
2022
false
false
false
France
neoplasm recurrence, local
Positron-Emission tomography
insurance, health, reimbursement
radiopharmaceuticals
fluorine radioisotopes
PSMA-1007
injections, intravenous
Fluorine F 18 PSMA-1007
guidelines for drug use
Biochemically Recurrent Prostate Carcinoma
PSMA-1007 (18F)
evaluation of the transparency committee
prostatic neoplasms
---